HDAC9 and ovarian cancer: Further, the platinum(IV) pro-drug compound B has demonstrated synergistic anticancer behavior between its cisplatin-core and PBA HDAC inhibitor ligands in cisplatin-sensitive and -resistant ovarian cancer cell lines [6, 35].